uniQure N.V. (NASDAQ: QURE) Faces Legal Challenges Amid Financial Struggles

Financial Performance - uniQure N.V. anticipates a quarterly loss of $0.93 per share with projected revenue of approximately $4.7 million [1][6] - The company has a negative price-to-earnings (P/E) ratio of -4.26, indicating a lack of profitability [3][6] - The price-to-sales ratio is 66.94, suggesting that investors are paying a high premium for each dollar of sales [3][6] - The enterprise value to sales ratio stands at 33.23, further reflecting financial challenges [3] Legal Challenges - uniQure is currently involved in a class action lawsuit for alleged violations of securities laws, which may impact its financial performance [2][6] - The lawsuit claims that the company made false and misleading statements regarding its Pivotal Study design and its comparison to the ENROLL-HD data set, contributing to delays in securing full FDA approval for its Biologics License Application (BLA) [2] - Additional class action lawsuits have been announced by the Schall Law Firm and Rosen Law Firm, targeting investors who purchased QURE shares between September 24, 2025, and October 31, 2025 [5] Financial Metrics - Despite financial struggles, uniQure maintains a relatively low debt-to-equity ratio of 0.29, indicating conservative debt usage [4] - The company's current ratio of 7.12 suggests strong liquidity, allowing it to cover short-term liabilities [4] - However, the negative enterprise value to operating cash flow ratio of -3.42 and an earnings yield of -23.48% highlight ongoing financial challenges [4]